Company intelligence / Profile preview

Treat Well Biotech

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Treat Well Biotech is a biopharmaceutical company focused on the development of innovative therapies for metabolic diseases, including obesity and type 2 diabetes. The company specializes in the design of multi-receptor agonists, specifically targeting the GLP-1, GIP, and glucagon receptors to achieve superior weight loss and glycemic control. Based in China, Treat Well Biotech leverages its expertise in peptide chemistry and metabolic signaling to advance a pipeline of next-generation incretin-based therapies. Their research aims to address the growing global burden of metabolic syndrome and related conditions like nonalcoholic steatohepatitis (NASH).

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Treat Well Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Treat Well Biotech.

Explore the full profile